Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing

Gastroenterology

Volumn 153, Issue 3, 2017, Pages 723-731.e1

  Chang, Jeff ^a,b,c   Leong, Rupert W ^a,b,c   Wasinger, Valerie C ^b   Ip, Matthew ^a,b   Yang, Michael ^a,b   Phan, Tri Giang ^b,d  

^a BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ANZAC Research Institute   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

CLE; Intestinal Barrier Function; Leaky Gut; Small Intestine

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; C REACTIVE PROTEIN;

ABDOMINAL PAIN; ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CD ACTIVITY INDEX SCORE; CONFOCAL LASER SCANNING MICROSCOPE; CONFOCAL LASER SCANNING MICROSCOPY; CONFOCAL LEAK SCORE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; FEMALE; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA PERMEABILITY; INTESTINE MUCOSAL HEALING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; CASE CONTROL STUDY; COLONOSCOPY; CONFOCAL MICROSCOPY; DIAGNOSTIC IMAGING; ERYTHROCYTE SEDIMENTATION RATE; INTESTINE MUCOSA; INTRAVITAL MICROSCOPY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERMEABILITY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; WOUND HEALING;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; INTESTINAL MUCOSA; INTRAVITAL MICROSCOPY; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PERMEABILITY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; WOUND HEALING;

EID: 85028771900     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.05.056     Document Type: Article

References (34)

1. Hanauer, S.B., Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:Suppl 1 (2006), S3–S9.
2. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3 (2006), 390–407.
3. Halpin, S.J., Ford, A.C., Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 107 (2012), 1474–1482.
4. Ballegaard, M., Bjergstrøm, A., Brøndum, S., et al. Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol 32 (1997), 569–571.
5. Jonefjall, B., Ohman, L., Simren, M., et al. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm Bowel Dis 22 (2016), 2630–2640.
6. Lopez, A., Ford, A.C., Colombel, J.F., et al. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials. Dig Liver Dis 47 (2015), 356–364.
7. Martínez, C., Lobo, B., Pigrau, M., et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 62 (2013), 1160–1168.
8. McGuckin, M.A., Eri, R., Simms, L.A., et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15 (2009), 100–113.
9. Fritscher-Ravens, A., Schuppan, D., Ellrichmann, M., et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 147 (2014), 1012–1020.
10. Kiesslich, R., Duckworth, C.A., Moussata, D., et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 61 (2012), 1146–1153.
11. Leong, R.W., Wong, B., Chen, J., et al. Intestinal mucosal leakage is detected using in vivo confocal endomicroscopy in macroscopically-normal Crohn's disease and ulcerative colitis. J Gastroenterol Hepatol, 27(Suppl 4), 2012, 109.
12. Geboes, K., Riddell, R., Ost, A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47 (2000), 404–409.
13. Baars, J.E., Nuij, V.J., Oldenburg, B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 18 (2012), 1634–1640.
14. Paramsothy, S., Leong, R.W., Endoscopy: Fluorescein contrast in confocal laser endomicroscopy. Nat Rev Gastroenterol Hepatol 7 (2010), 366–368.
15. Chang, J., Ip, M., Yang, M., et al. The learning curve, interobserver, and intraobserver agreement of endoscopic confocal laser endomicroscopy in the assessment of mucosal barrier defects. Gastrointest Endosc 83 (2016), 785–791.
16. Leong, R.W., Arshi, M., Chang, J., et al. Acute tumour necrosis factor administration induces transient epithelial cell shedding, mucosal leak and neutrophil recruitment to the gut in a mouse model. J Gastroenterol Hepatol, 29(Suppl 2), 2014, 11.
17. Liu, J.J., Madsen, K.L., Boulanger, P., et al. Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. J Clin Gastroenterol 45 (2011), 240–245.
18. Yang, M.Y., Leong, R.W., Wong, B., et al. Intestinal barrier dysfunction as identified by confocal endomicroscopy in macroscopically normal terminal is useful in detecting inflammatory bowel disease and predicting requirements for treatment escalation [abstract]. J Gastroenterol Hepatol, 28(Suppl 2), 2013, 28.
19. Leong, R.W., Nguyen, N.Q., Meredith, C.G., et al. In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology 135 (2008), 1870–1876.
20. Vivinus-Nébot, M., Frin-Mathy, G., Bzioueche, H., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63 (2014), 744–752.
21. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; Mar 2011; Available at: http://handbook.cochrane.org/chapter_7/7_7_3_5_mediansand_interquartile_ranges.htm. Accessed August 1, 2015.
22. Odenwald, M.A., Turner, J.R., Intestinal permeability defects: is it time to treat?. Clin Gasroenterol Hepatol 11 (2013), 1075–1083.
23. Liu, K., Mill, J., Wong, B., et al. Intestinal barrier dysfunction measured with confocal endomicroscopy in macroscopically normal mucosa can predict requirement for treatment escalation. Gastrointest Endosc, 77, 2013, S206.
24. Lovell, R.M., Ford, A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10 (2012), 712–721.
25. Keohane, J., O'Mahony, C., O'Mahony, L., et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol 105 (2010), 1789–1794.
26. Schoepfer, A.M., Beglinger, C., Straumann, A., et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105 (2010), 162–169.
27. Lahiff, C., Safaie, P., Awais, A., et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 37 (2013), 786–794.
28. Lewis, J.D., Chuai, S., Nessel, L., et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 14 (2008), 1660–1666.
29. Sandborn, W.J., Feagan, B.G., Marano, C., et al. PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
30. Suenaert, P., Bulteel, V., Lemmens, L., et al. Anti–tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97 (2002), 2000–2004.
31. Noth, R., Stüber, E., Häsler, R., et al. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease. J Crohns Colitis 6 (2012), 464–469.
32. Simrén, M., Axelsson, J., Gillberg, R., et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 97 (2002), 389–396.
33. Alonso, C., Guilarte, M., Vicario, M., et al. Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability. Neurogastroenterol Motil 24 (2012), 740–746.
34. Humphris, J., Swartz, D., Egan, B.J., Leong, R.W., Status of confocal laser endomicroscopy in gastrointestinal disease. Trop Gastroenterol 33 (2012), 9–20.